Guidant's Acculink Is Exclusive CREST Stent; Trial Begins in Six Months
This article was originally published in The Gray Sheet
Guidant has the option of evaluating an emboli protection device along with its Acculink self-expanding carotid stent in the 2,500-patient Carotid Revascularization Endarterectomy Stenting Trial (CREST), according to study investigators.
You may also be interested in...
Johnson & Johnson Cordis plans to submit an investigational device exemption application to FDA in March or April for the SAPPHIRE carotid stent trial, as discussions continue with the Health Care Financing Administration to secure reimbursement coverage.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.